Karallief’s plant-based nutraceutical powder clinically shown to fortify immune system
28 Mar 2024 --- US-based nutraceutical ingredient company Karallief has released its latest multi-herbal extract formula, KaraShield. The formula has been granted a US patent and was assessed in a randomized, double-blind clinical study to test its effectiveness in supporting a healthy immune system.
“In the clinical study, KaraShield brought a marked decrease in the occurrence and severity of common upper respiratory symptoms, which are well-documented to have negative impacts in nearly every aspect of daily life, from mood to energy and concentration,” says Krishna Rajendran, CEO of Karallief, which develops and distributes clinically studied combination herbal extract ingredients.
“The findings of the latest KaraShieldM study allow us to provide yet another clinically tested multi-herbal/combination formula supplement to support health, wellness and vitality. KaraShield joins our latest products — KaraHeart for cardiovascular support, Easy Climb for joint health support and KaraLiv for liver health support — to further expand Karallief’s contributions to holistic wellness.”
Plant-based powder for food supplements
KaraShield is a proprietary herbal formula comprising 500 mg of herbal ingredients such as Andrographis paniculata, Withania somnifera, Moringa oleifera and Ocimum sanctum that support immune function and can be consumed once a day. The extract is available in powder form, which formulators and finished product manufacturers can use to create food supplements, foods and beverages.
The ingredients in KaraShield have been standardized to a specific active compound and are blended to an exact blending ratio. These factors make the blend synergistic and contribute to its efficacy.
The human clinical study of KaraShield, published in the International Journal of Basic & Clinical Pharmacology, concluded that the healthy participants taking KaraShield outperformed the placebo group, observing significant decreases in the frequency and severity of common upper respiratory tract symptoms, high-sensitivity C-reactive protein levels and substantial increases in Immunoglobulin G levels. The fast-acting product supports a healthy immune system in about seven days.
Improves immunoglobulin shield
The clinical trial included 120 healthy, disease-free patients with at least two clinically confirmed common upper respiratory tract symptoms two months before enrollment. They were divided equally into two groups, one receiving KaraShield and the other receiving a placebo.
Compared to the placebo, KaraShield showed an 82% decrease in upper respiratory tract symptoms frequency compared with 39% in the placebo group. There was an 83% decrease in the severity of upper respiratory tract symptoms compared with 35% in the placebo. Serum Immunoglobulin G increased by 12% compared with a 5% decrease for the placebo group.
“Immunoglobulins are the outer layer of defense for the human immune system, helping fight infections before they start and preventing minor issues from escalating,” says Dr. Frank Lichtenberger, immunologist and scientific advisor at Karallief.
“For the first time, to my knowledge, a safe plant-based product has been shown to improve this immunoglobulin shield while also enhancing its efficiency and preventing waste. In our modern era of rampant human-to-human contagion, bolstering our immune defenses is vital.”
KaraShield also decreased the C-reactive protein (indicating inflammatory response) by 47% and demonstrated a 61% improvement in the ability to engage in daily functions over the placebo 33%. Overall, feelings of wellness increased by 35%.
In 2022, Karallief was granted a US patent for Easy Climb, a fast-acting herbal extract formula that relieves occasional joint discomfort.
In addition, the company provided clinical evidence that Easy Climb improves osteoarthritis symptoms and mobility in as little as 30 days.
By Inga de Jong
To contact our editorial team please email us at editorial@cnsmedia.com
Subscribe now to receive the latest news directly into your inbox.